# Chris Picardo

> Chris Picardo is a seed investor at Madrona (Seattle) backing Biotechnology and Biopharma. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Madrona](https://shizune.co/investors/profile/madrona-venture-group)
- Location: Seattle, United States
- Total investments: 7
- Last investment: Aug 2026
- Lead investor: 86%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/chrispicardo

Chris Picardo is a Partner at Madrona Venture Group.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 57% |
| Biopharma | 2 | 29% |
| InsurTech | 2 | 29% |
| Health Care | 2 | 29% |
| Therapeutics | 2 | 29% |

17 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 3 | 43% |
| Series A | 2 | 29% |
| Series B | 1 | 14% |
| Series C | 1 | 14% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 5 | 71% |
| Israel | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Faye | Faye provides whole-trip travel coverage and care that brings out the best in each journey with industry-leading technology that enables smarter, faster, smoother assistance and claims resolutions. Our robust travel insurance covers your health, your trip, your stuff, and even your pet, via an app that provides real-time proactive solutions,quick reimbursements and 24/7 customer experience specialists who turn travel mishaps into laugh-about-it-later memories. Join our team of travel and insurance experts as we set a new standard by overdelivering in an industry oftentimes synonymous with doing the opposite. | $50M | Series C | Aug 05, 2026 |  |
| Anzen | Anzen is a management insurance and operations tool using real-time HRIS and SaaS integrations to identify and avoid management risks. The company was founded in 2020 and is headquartered in San Francisco, California, United States. | $16M | Series A | Nov 13, 2025 |  |
| Aizen Therapeutic | Aizen is an AI-driven biotechnology company that is pioneering the development of Mirror Peptides, a novel class of biologic medicines. | $13M | Seed | Nov 21, 2024 |  |
| Archon Biosciences | Archon is a biotechnology firm that creates computationally engineered proteins to unleash potent therapeutic targets beyond the grasp of current methods and improve disease management. | $20M | Seed | Oct 30, 2024 |  |
| Terray Therapeutics | Terray Therapeutics is a biotechnology company that integrates experimentation and computation to enhance small molecule drug discovery. The platform generates extensive, precise data through a rapid design-make-test-analyze cycle, allowing for efficient exploration of chemical space. By focusing on both wet lab science and AI, the companyaddresses complex therapeutic challenges across various targets. | $120M | Series B | Oct 17, 2024 |  |
| Terray Therapeutics | Terray Therapeutics is a biotechnology company that integrates experimentation and computation to enhance small molecule drug discovery. The platform generates extensive, precise data through a rapid design-make-test-analyze cycle, allowing for efficient exploration of chemical space. By focusing on both wet lab science and AI, the companyaddresses complex therapeutic challenges across various targets. | $60M | Series A | Feb 15, 2022 |  |
| Modulus Therapeutics | Modulus Therapeutics is an artificial-intelligence-powered cell therapy design company. | $3.5M | Seed | Jul 15, 2021 |  |

7 of 7 investments shown.

## Co-investors
- [XTX Ventures](https://shizune.co/investors/profile/xtx-ventures) — VC Fund, 4 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 3 deals together
- [Two Sigma Ventures](https://shizune.co/investors/profile/two-sigma-ventures) — VC Fund, 3 deals together
- [Digitalis Ventures](https://shizune.co/investors/profile/digitalis-ventures) — VC Fund, 2 deals together
- [Goldcrest Capital](https://shizune.co/investors/profile/goldcrest-capital-2) — VC Fund, 2 deals together
- [KdT Ventures](https://shizune.co/investors/profile/kdt-ventures) — VC Fund, 2 deals together

## About Madrona

VC Fund · Seattle, United States

Madrona Venture Group is a Seattle-based venture capital firm. The firm prefers to invest in businesses that are involved in information technology, e-commerce, digital media, advertising, software, gaming, data, analytics, mobile, and infrastructure.

5 contacts available at Madrona.

| Name | Title | Profile |
| --- | --- | --- |
| Chris Picardo | Senior Associate | https://shizune.co/investors/profile/chris-picardo |
| Hope Cochran | Managing Director | https://shizune.co/investors/profile/hope-f-cochran |
| John Torrey | Venture Partner | https://shizune.co/investors/profile/john-torrey |
| Jon Turow | Partner | https://shizune.co/investors/profile/jon-turow |
| Len Jordan | Managing Director | https://shizune.co/investors/profile/len-jordan |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Chris Picardo invest in?

Chris Picardo invests primarily in Biotechnology, Biopharma and InsurTech startups, most often at Seed and Series A stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Chris Picardo last invest?

The most recent investment recorded for Chris Picardo closed in Aug 2026. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co